BOSTON, Dec. 10 /PRNewswire-FirstCall/ -- Solos Endoscopy, Inc. is pleased to announce that the Company increased sales revenue for the month of October 2008 by over 10% compared to the same time period for 2007. Revenues generated during October 2008 reached $ 31,508 as compared with $28,509 for the same month last year. This marks the second consecutive year that the Company's revenue has increased for the month of October.
The Mammo View(TM) system has expanded Solos' product line to reach a broader vertical market. The Company has received numerous purchase orders, and shipping systems to hospitals around the U.S. The Mammo View(TM) system contains versatile and customizable medical equipment that can support multiple procedures including biopsies, lumpectomies, and other intraductal procedures. The Mammo View(TM) has the potential to help the early diagnosis of more than 1 million cases of breast cancer discovered each year throughout the world.
"October is typically a slow month for our surgical sales, however, this year we have continued to grow our October sales revenue. We believe our Mammo View (TM) line will continue to improve our profitability and will have a highly positive effect on the Company's financials within the coming New Year," stated Bob Segersten, President of Solos Endoscopy, Inc.
About Solos Endoscopy, Inc.:
Solos Endoscopy, Inc. is a healthcare technology company whose mission is to develop and market breakthrough technology, applications, medical devices, and procedural techniques for the screening, diagnosis, treatment and management of medical conditions. Backed by technical support, Solos' sales team can help make the right buying decisions for the hospital, surgery center, or physician office. Additional information is available on the Company's website at: www.solosendoscopy.com.
Safe Harbor: This release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 27E of the Securities Act of 1934. Statements contained in this release that are not historical facts may be deemed to be forward-looking statements. Investors are cautioned that forward-looking statements are inherently uncertain. Actual performance and results may differ materially from that projected or suggested herein due to certain risks and uncertainties including, without limitation, ability to obtain financing and regulatory and shareholder approval for anticipated actions.
CONTACT: Investor Relations for Solos Endoscopy, Inc., +1-866-THE-APPL(E)
Web site: http://www.solosendoscopy.com//
